Cargando…
Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC),...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860016/ https://www.ncbi.nlm.nih.gov/pubmed/36670176 http://dx.doi.org/10.1038/s41598-023-28344-2 |
_version_ | 1784874479306932224 |
---|---|
author | Adhia, Divya Bharatkumar Mani, Ramakrishnan Mathew, Jerin O’Leary, Finella Smith, Mark Vanneste, Sven De Ridder, Dirk |
author_facet | Adhia, Divya Bharatkumar Mani, Ramakrishnan Mathew, Jerin O’Leary, Finella Smith, Mark Vanneste, Sven De Ridder, Dirk |
author_sort | Adhia, Divya Bharatkumar |
collection | PubMed |
description | Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC), and somatosensory cortex (SSC), respectively]. This pilot study, conducted in a university setting, evaluated the feasibility, safety, and acceptability of a novel electroencephalography-based infraslow-neurofeedback (EEG ISF-NF) technique for retraining activities in pgACC, dACC and SSC and explored its effects on pain and disability. Participants with CLBP (n = 60), recruited between July’20 to March’21, received 12 sessions of either: ISF-NF targeting pgACC, dACC + SSC, a ratio of pgACC*2/dACC + SSC, or Placebo-NF. Descriptive statistics demonstrated that ISF-NF training is feasible [recruitment rate (7 participants/month), dropouts (25%; 20–27%), and adherence (80%; 73–88%)], safe (no adverse events reported), and was moderate to highly acceptable [Mean ± SD: 7.8 ± 2.0 (pgACC), 7.5 ± 2.7 (dACC + SCC), 8.2 ± 1.9 (Ratio), and 7.7 ± 1.5 (Placebo)]. ISF-NF targeting pgACC demonstrated the most favourable clinical outcomes, with a higher proportion of participants exhibiting a clinically meaningful reduction in pain severity [53%; MD (95% CI): − 1.9 (− 2.7, − 1.0)], interference [80%; MD (95% CI): − 2.3 (− 3.5, − 1.2)], and disability [73%; MD (95% CI): − 4.5 (− 6.1, − 2.9)] at 1-month follow-up. ISF-NF training is a feasible, safe, and an acceptable treatment approach for CLBP. |
format | Online Article Text |
id | pubmed-9860016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98600162023-01-22 Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial Adhia, Divya Bharatkumar Mani, Ramakrishnan Mathew, Jerin O’Leary, Finella Smith, Mark Vanneste, Sven De Ridder, Dirk Sci Rep Article Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC), and somatosensory cortex (SSC), respectively]. This pilot study, conducted in a university setting, evaluated the feasibility, safety, and acceptability of a novel electroencephalography-based infraslow-neurofeedback (EEG ISF-NF) technique for retraining activities in pgACC, dACC and SSC and explored its effects on pain and disability. Participants with CLBP (n = 60), recruited between July’20 to March’21, received 12 sessions of either: ISF-NF targeting pgACC, dACC + SSC, a ratio of pgACC*2/dACC + SSC, or Placebo-NF. Descriptive statistics demonstrated that ISF-NF training is feasible [recruitment rate (7 participants/month), dropouts (25%; 20–27%), and adherence (80%; 73–88%)], safe (no adverse events reported), and was moderate to highly acceptable [Mean ± SD: 7.8 ± 2.0 (pgACC), 7.5 ± 2.7 (dACC + SCC), 8.2 ± 1.9 (Ratio), and 7.7 ± 1.5 (Placebo)]. ISF-NF targeting pgACC demonstrated the most favourable clinical outcomes, with a higher proportion of participants exhibiting a clinically meaningful reduction in pain severity [53%; MD (95% CI): − 1.9 (− 2.7, − 1.0)], interference [80%; MD (95% CI): − 2.3 (− 3.5, − 1.2)], and disability [73%; MD (95% CI): − 4.5 (− 6.1, − 2.9)] at 1-month follow-up. ISF-NF training is a feasible, safe, and an acceptable treatment approach for CLBP. Nature Publishing Group UK 2023-01-20 /pmc/articles/PMC9860016/ /pubmed/36670176 http://dx.doi.org/10.1038/s41598-023-28344-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Adhia, Divya Bharatkumar Mani, Ramakrishnan Mathew, Jerin O’Leary, Finella Smith, Mark Vanneste, Sven De Ridder, Dirk Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title | Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title_full | Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title_fullStr | Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title_full_unstemmed | Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title_short | Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
title_sort | exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860016/ https://www.ncbi.nlm.nih.gov/pubmed/36670176 http://dx.doi.org/10.1038/s41598-023-28344-2 |
work_keys_str_mv | AT adhiadivyabharatkumar exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT maniramakrishnan exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT mathewjerin exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT olearyfinella exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT smithmark exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT vannestesven exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial AT deridderdirk exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial |